Cetera Trust Company N.A Acquires New Shares in Amgen Inc. (NASDAQ:AMGN)

Cetera Trust Company N.A bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,288 shares of the medical research company’s stock, valued at approximately $2,963,000. Amgen comprises about 1.8% of Cetera Trust Company N.A’s portfolio, making the stock its 11th biggest holding.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. OFI Invest Asset Management acquired a new stake in shares of Amgen in the third quarter valued at $26,000. Briaud Financial Planning Inc purchased a new stake in Amgen during the third quarter worth about $26,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Amgen during the first quarter worth about $28,000. BOK Financial Private Wealth Inc. purchased a new position in shares of Amgen in the fourth quarter valued at approximately $29,000. Finally, Providence Capital Advisors LLC acquired a new position in shares of Amgen in the third quarter valued at approximately $30,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Raymond James assumed coverage on Amgen in a report on Thursday, March 28th. They issued a “market perform” rating for the company. The Goldman Sachs Group lifted their price target on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Finally, UBS Group reduced their price objective on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a report on Wednesday. Ten investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Price Performance

Shares of AMGN stock traded up $6.18 during trading hours on Friday, hitting $268.93. The company’s stock had a trading volume of 3,380,330 shares, compared to its average volume of 2,077,465. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The business has a fifty day moving average of $276.90 and a 200-day moving average of $281.40. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The stock has a market cap of $144.25 billion, a price-to-earnings ratio of 21.53, a P/E/G ratio of 2.50 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter in the prior year, the firm earned $4.09 EPS. Amgen’s quarterly revenue was up 19.8% on a year-over-year basis. As a group, equities research analysts anticipate that Amgen Inc. will post 19.45 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.35%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.